Our Technologies initiatives covers projects executed in close collaboration with pRED and Roche teams to solve portfolio-relevant challenges. They aim to improve and prototype the scale-up of organoids and expected outcomes are validated, ready-to-use assays, as well as characterised and qualified models.
The Organoid Farm laboratory industrializes organoid production by scaling, standardizing and automating organoid culture protocols. The goal of this team is to develop a suite of technologies for mass production of organoids, for example, to enable organoid-based high-content screening applications.
The Phenotyping team develops high-throughput methods for studying and screening complex biological systems such as organoids and patient-derived tissues. These miniaturized automated solutions leverage bioengineering and microfluidics and are suitable for complex quantitative profiling analyses to understand underlying biological processes in healthy and diseased conditions.
These high-throughput assays are used by IHB and pRED researchers throughout the drug development process, from drug screening campaigns to safety studies.
We are always looking for talented individuals.